Cyclacel Pharmaceuticals (CYCC) announced that it expects to implement a 1-for-16 reverse stock split on its shares of common stock effective May 12, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L884.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC:
- Cyclacel Pharmaceuticals Enters Share Exchange Agreement
- Cyclacel Pharmaceuticals enters exchange agreement with Fitters
- Biotech Alert: Searches spiking for these stocks today
- Cyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holders
- Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development